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Background: Transient Receptor Potential Vanilloid 1 (TRPV1) confers noxious heat and inﬂammatory pain
signals in the peripheral nervous system. Clinical trial of resiniferatoxin from Euphorbia species is successfully
aimed at TRPV1 in cancer pain management and heading toward new selective painkiller status that further
validates this target for drug discovery eﬀorts. Evodia species, used in traditional medicine for hundreds of years,
are a recognised source of diﬀerent TRPV1 agonists, but no antagonist has yet been reported.
Hypothesis/Purpose: In a search for painkiller leads, we noted for the ﬁrst time a TRPV1 antagonist activity in the
fresh fruits of Tetradium daniellii (Benn.) T.G. Hartley (syn. Evodia hupehensis Dode).
Methods: Through a combination of extraction and puriﬁcation methods with functional TRPV1-speciﬁc Ca2+
uptake assays (bioactivity-guided fractionation/isolation/puriﬁcation); we isolated a new painkiller candidate
that is a distant structural homologue of capsiate exovanilloids and endovanilloids such as anandamide, but a
putative competitive inhibitor of the TRPV1. Four additional inactive compounds (N-isobutyl-4,5-epoxy-2E-
decadienamide, geranylpsoralen, 8-(7′,8′-epoxygeranyloxy)psoralen, and xanthotoxol) were also co-puriﬁed
with pellitorine. Their structures were established by extensive 1D- and 2D-NMR spectroscopic analysis.
Results: 1H- and 13C NMR determination of the chemical structure revealed it to be pellitorine, (2E,4E)-N-(2-
methylpropyl)deca-2,4-dienamide, which can compete structurally with algesics released in inﬂammation. In
contrast to previous isolates from Evodia species, pellitorine blocked capsaicin-evoked Ca2+ uptake with an IC50
of 154 µg/ml (0.69mM/l). N-Isobutyl-4,5-epoxy-2E-decadienamide and geranylpsoralen, 8-(7′,8′-epoxyger-
anyloxy)psoralen, and xanthotoxol did not aﬀect the TRPV1.
Conclusion: This is the ﬁrst evidence that pellitorine, an aliphatic alkylamide analogue of capsaicin, can serve as
an antagonist of the TRPV1 and may inhibit exovanilloid-induced pain.
Introduction
Transient Receptor Potential Vanilloid 1 (TRPV1), one of 28 mem-
bers of the transient receptor potential (TRP) family of ion channels,
transduces pain signals in the peripheral nervous system (PNS) of
mammals, including human. TRPV1 expressing nerve endings of C- and
Aδ-type primary aﬀerent nociceptive neurons are triggered by endo-,
and exovanilloids, moderate heat (Tominaga et al., 1998), and acute or
chronic inﬂammatory mediators, either lipid-like eicosanoids
(Olah et al., 2001; Zygmunt et al., 1999; Hwang et al., 2000) or sen-
sitized by peptides such as bradykinin (Pan and Chen, 2004; Di Marzo
et al., 2002). Moreover, metabolic changes leading to tissue
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acidiﬁcation potentiate the receptor for chronic pain signalling
(Caterina et al., 1997; Tominaga et al., 1998).
Pain sensation can be reduced by the inhibition of TRPV1, and
therefore identiﬁcation of potent TRPV1 antagonists have been in the
focus of research studies. Capsazepine, the ﬁrst TRPV1 antagonist, was
reported by Bevan et al. (1992). Since the identiﬁcation of TRPV1,
numerous TRPV1 antagonists have been synthetized. An eﬃcient an-
tagonist like SB-705,498 (Gunthorpe et al., 2007) showing IC50 values
at nanomolar range has been demonstrated to block the activation of
TRPV1 by capsaicin, heat, and decreased pH. However, potent an-
tagonists of TRPV1 have exhibited undesirable chemical, pharmacolo-
gical or pharmacokinetic properties such as poor solubility causing
decreased absorption (Stec et al., 2008), short half-life (Tafesse et al.,
2004), severe hyperthermia (Gavva et al., 2008; Tamayo et al., 2008) or
low oral bioavailability (Tafesse et al., 2004). The most eﬀective an-
tagonists such as SB-705498, NEO6860 or JNJ-39439335 have been
investigated in clinical trials to evaluate their safety and eﬃcacy in the
treatment of various pain-associated conditions. Phase I and II studies
of the above mentioned compounds have been completed without
publication of results or terminated because of insuﬃcient number of
study subjects.
It is perhaps not surprising that number of plant species have
evolved secondary metabolites, which target the TRPV1 in mammals to
defend themselves. Thus, RTX and analogous irritant vanilloid phyto-
toxins most likely have evolved to repel herbivorous mammals. From
the Evodia genus evodiamine and rutaecarpine have been described as
moderate agonists of the TRPV1 (Pearce et al., 2004; Deng and Li, 2005;
Wang et al., 2005; Yi et al., 2004; Yu et al., 2005). However, there has
as yet no report of any antagonist which may inhibit pain through
competition with bona ﬁde endovanilloids at binding site of the TRPV1.
We have therefore investigated Tetradium. daniellii in a search for new
vanilloid analogues targeting the TRPV1 either as agonists or antago-
nists.
Materials and methods
For vacuum liquid chromatography (VLC) TLC silica gel 60 G 15 µm
(Merck, Darmstadt, Germany) was used. For open column chromato-
graphy (OCC) LiChroprep RP-18 (40–63 µm, Merck, Darmstadt,
Germany) was applied. Preparative TLC was carried out on 20× 20 cm
silica gel (Silica gel 60 F254, Merck, Darmstadt, Germany) plates.
Rotation planar chromatography (RPC) was performed using
Chromatotron (Model 8924, Harrison Research, Palo Alto, CA, USA) on
manually prepared silica gel layer, thickness 2mm (Silica gel 60 GF254,
Merck, Darmstadt, Germany). Chromatographic fractions were mon-
itored by TLC on silica gel (Merck 5715), visualized by spraying with
conc. H2SO4, followed by heating. NMR spectra were recorded in CDCl3
on a Bruker Avance DRX 500 spectrometer at 500MHz (1H) or 125MHz
(13C); the signals of the deuterated solvent were taken as the reference.
All chemicals and reagents were commercially available. Analytical
grade reagents were used during the extraction of plant material. For
HPLC separation, high purity solvents for HPLC were used. During in
vitro and in vivo assays, tissue culture quality chemicals or solvents were
used.
Plant material
The fruits of T. daniellii were collected in a public park at
Hódmezővásárhely (Hungary) in September, and were stored at−15 °C
until preparation. A voucher specimen (No. 760) has been deposited in
the Herbarium of the Department of Pharmacognosy, University of
Szeged, Szeged, Hungary.
Extraction and isolation
The frozen plant material (10 kg) was percolated with MeOH (60 l)
at room temperature. After concentration to 1.5 l, the MeOH extract
was partitioned between cyclohexane (4×1.5 l), CHCl3 (4× 1.5 l) and
H2O. The cyclohexane layer was dried in vacuum yielding a dark green
oily residue (110 g), which was subjected to VLC (VLC-1) on silica gel,
using a gradient system of cyclohexane – EtOAc – EtOH (100:0:0,
19:1:0, 9:1:0, 4:1:0, 7:3:0, 70:30:3, 15:10:1, and 1:1:1). Altogether 83
fractions, each of 250ml, were collected and successively combined in
18 fractions (Evo1 – Evo18) after TLC monitoring. Combined fractions
Evo10, eluted with cyclohexane – EtOAc – EtOH (4:1) exhibited cap-
saicin (CAPS)-induced Ca2+-uptake inhibitory activity, and were fur-
ther fractionated by means of VLC (VLC-2) on silica gel with n-hexane –
acetone mixtures of increasing polarity (19:1, 9:1, 17:3, 4:1, 3:1, 7:3,
and 3:2). The fractions obtained here were combined in nine main
fractions (Evo10/1 – Evo10/9) depending on their compositions. Only
one fraction (Evo10/1) was found to be eﬀective, and was re-chroma-
tographed by OCC on RP-18 silica gel with elution of 70, 75, 80, 85, 90,
95 and 100% MeOH. The combined fractions (Evo10/1/A – Evo10/1/
H) from this separation were assayed for their eﬃcacy, and the active
fraction Evo10/1/B was selected for further chromatography. This
fraction was puriﬁed by preparative TLC on silica gel using CHCl3 –
acetone (49:1) as developing system, to aﬀord pellitorine (1) (2.4 mg)
(Fig. 4). after three-step chromatographic separations using VLC (silica
gel, n-hexane – acetone gradient), RPC (silica gel, toluene – ethyl
acetate gradient) and preparative TLC (silica gel, CHCl3 – acetone 19:1),
combined fractions 29–33 from the VLC-1 separation yielded N-iso-
butyl-4,5-epoxy-2E-decaenamide (3) (1.2 mg), 8-geranyloxypsoralen
(5) (150mg), 8-(7′,8′-epoxygeranyloxy)psoralen (7) (2.3 mg) and xan-
thotoxol (4) (4.3 mg) (Fig. 4).
(2E,4E)-N-(2-methylpropyl)deca-2,4-dienamide (=pellitorine) (1):
amorphous solid; 1H NMR (500MHz, CDCl3, δ ppm): 5.74 (1H, d,
J=15.0 Hz, H-2), 7.18 (1H, dd, J=15.0, 10.2 Hz, H-3), 6.12 (1H, dd,
J=15.2, 10.4 Hz, H-4), 6.07 (1H, dt, J=15.1, 6.4 Hz, H-5), 2.13 (2H,
dt, J=7.2, 6.9 Hz, H-6), 1.39 (2H, m, H-7), 1,32 – 1,2 (4H, m, H-8, H-
9), 0.87 (3H, t, J=7.0 Hz, H-10), 3.15 (1H, t, J=6.5 Hz, H-1′), 1.79
(1H, sept, J=6.7 Hz, H-2′), 0.92 (6H, d, J=6.7 Hz, H-3′,4′), 5.49 (1H,
brs, NH). The data are identical with those published by Ley et al.
(2004).
N-isobutyl-4,5-epoxy-2E-decaenamide (2): amorphous solid; 1H
NMR (500MHz, CDCl3,δ ppm): 6.06 (1H, d, J=15.2 Hz, H-2), 6.65
(1H, dd, J=15.2, 6.4 Hz, H-3), 3.19 (1H, brd, J=6.4 Hz, H-4), 2.85
(1H, dt, J=6.4, 1.9 Hz, H-5), 1.60 (2H, m, H-6), 1.43 (2H, m, H-7),
1.32 (4H, m, H-8, H-9), 0.90 (3H, t, J=7.3 Hz, H-10), 3.16 (1H, t,
J=6.5 Hz, H-1′), 1.80 (1H, sept, J=6.7 Hz, H-2′), 0.93 (6H, d,
J=6.7 Hz, H-3′,4′), 5.5 (1H, brs, NH). The data are in good agreement
with those published by Wei et al. (2004).
8-Geranyloxypsoralen (3): white crystals; mp. 57–59 °C; 1H NMR
(500MHz, CDCl3,δ ppm): 6.35 (1H, d, J=9.6 Hz, H-3), 7.75 (1H, d,
J=9.6 Hz, H-4), 7.35 (1H, s, H-5), 6.80 (1H, d, J=2.1 Hz, H-6), 7.68
(1H, d, J=2.1 Hz, H-7), 5.01 (3H, m, H-1′, H-7′), 5.59 (2H, t,
J=7.0 Hz, H-2′), 1.69 (3H, s, H-4′), 2.00 (4H, m, H-5′, H-6′), 1.56 (3H,
s, H-9′), 1.64 (3H, s, H-10′); 13C NMR (125MHz, CDCl3, δ ppm): 160.5
(C-2), 114.7 (C-3), 144.3 (C-4), 113.2 (C-5), 106.7 (C-6), 146.6 (C-7),
143.1 (C-8), 144.0 (C-9), 116.5 (C-10), 125.8 (C-11), 149.0 (C-12), 70.1
(C-1′), 119.4 (C-2′), 131.6 (C-3′), 16.5 (C-4′), 39.6 (C-5′), 26.3 (C-6′),
123.8 (C-7′), 131.7 (C-8′), 17.6 (C-9′), 25.6 (C-10′). NMR chemical
shifts are in good agreement with the published values (Miyake et al.,
1999).
8-(7′,8′-Epoxygeranyloxy)psoralen (4): amorphous solid; 1H NMR
(500MHz, CDCl3,δ ppm): 6.37 (1H, d, J=9.6 Hz, H-3), 7.76 (1H, d,
J=9.6 Hz, H-4), 7.36 (1H, s, H-5), 6.81 (1H, d, J=2.1 Hz, H-6), 7.69
(1H, d, J=2.1 Hz, H-7), 5.03 (2H, d, J=7.1 Hz, H-1′), 5.65 (2H, t,
J= 7.1 Hz, H-2′), 1.73 (3H, s, H-4′), 2.17 (1H, m, H-5′), 2.14 (1H, m, H-
5′), 1.59 (2H, m, H-6′), 2.64 t (1H, J=6.2 Hz, H-7′), 1.24 (3H, s, H-9′),
1.28 (3H, s, H-10′). The data are in good agreement with those pub-
lished by Ziegler and Spiteller (1992).
Xanthotoxol (5): white crystal; mp. 249–250 °C. Identiﬁcation of 5
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was on the basis of its TLC co-elution with authentic standard and on its
1H NMR spectrum (Harkar et al., 1984).
CAPS and capsazepine (CapZ), a well characterized antagonist of
TRPV1, were dissolved in DMSO (all from Sigma, St. Louis, MO, USA).
RTX (LC Laboratories, Woburn, MA, USA) was dissolved in ethanol at
2mg/ml concentration and further diluted in ddH2O.
Cell culture and preparation of permanent TRPV1-HaCaT cell line
The spontaneously immortalized human keratinocyte cell line
HaCaT was kindly provided by Dr. Fusenig, Heidelberg, Germany
(Boukamp et al., 1988), and cultured in MIXMEM medium supple-
mented with 10% FCS (Sigma-Aldrich, St. Louis, MO, USA).
The C-terminally tagged rat TRPV1ε DNA (accession number:
NM_031982.1) construct was prepared in the plasmid vector containing
metallothionein promoter (pMTH) as described previously (Olah et al.,
2001). To avoid the decrease in cell survival that occurs when the
TRPV1 is overexpressed, only the basal activity of the inducible me-
tallothionein promoter was used. To prepare a cell line permanently
expressing the TRPV1, HaCaT cells were transfected with the plasmid
vector using the Exgen 500 reagent according to the recommendations
of the manufacturer. After 24 h cells were transferred to selection
medium, containing 0.8mg/ml G418 (Sigma, St. Louis, MO, USA)
which was replaced every second day. After about a month, G418-re-
sistant colonies were tested with vanilloid-induced 45Ca2+ uptake as-
says and a colony exhibiting 20-fold above the base line uptake was
chosen for further studies.
45Ca2+ uptake assay
One day before the assay, cells were seeded in 96-well ﬂat bottom
plates (Orange Scientiﬁc, Braine-l'Alleud, Belgium) at a density of
20,000 cells/well and left for duplication O/N. The assays were per-
formed with a BioMek 1000 robotized liquid handler (Beckman
Instruments Inc., Fullerton, CA, USA). The plates were washed three
times with assay medium (Ca2+- and Mg2+-free Hanks’ balanced salt
solution supplemented 0.8 mM MgCl2 and with 25mM Tris-HCl,
pH=7.4). CAPS dilutions in the presence of 45Ca2+ were prepared by
the robot. The Ca2+ uptake assay was performed for 10min at 24 °C
using 0.07 µCi of 45Ca2+ in 100 µl ﬁnal volume/well. To terminate
45Ca2+ uptake and remove the free isotope, cells were washed three
additional times and then lysed in 100 µl/well lysis buﬀer (50mM Tris-
HCl, pH 7.5, 150mM NaCl, 1% Triton X-100, 0.1% SDS, 5mM EDTA)
for 30min. Eighty µl aliquots of the solubilized cell extracts were mixed
with 120 µl aliquots of Optiphase Supermix scintillation cocktail
(Perkin Elmer, Wellesley, MA, USA) and counted in a Perkin Elmer li-
quid scintillation counter.
Eye wipe test
Hundred µM of CAPS solution in 0.05% of methylcellulose or
100 µM of CAPS solution supplemented with 3.75mM of pellitorine in
0.05% of methylcellulose was dropped into the eyes of the BALB/c mice
and the number of defensive wiping movements was counted for 2min.
Two-tailed t-test was used for statistical analysis. The group number
was 7 or higher.
Results and discussion
The extraction and the puriﬁcation of cyclohexane phase of fruits of
Tetradium daniellii (Benn.) T.G. Hartley (syn. Evodia hupehensis Dode)
resulted in the isolation of ﬁve compounds. The concentrated MeOH
extracts were partitioned between cyclohexane, CHCl3 and H2O. VLC
separation of the active component containing cyclohexane fraction
(Fig. 1A) on silica gel, using a gradient system of cyclohexane/EtOAc/
EtOH, resulted 18 fractions with diﬀerent composition (Evo1 – Evo18).
Fraction Evo10 exhibited antagonist activity on CAPS-induced 45Ca2+
uptake in the TRPV1-HaCaT keratinocyte cell line (Fig. 1B). To test the
antagonist activity of the extracts, the TRPV1-HaCaT cells were acti-
vated for maximal 45Ca2+ uptake with 2 µM CAPS, a sub-maximum
dose that was stringent enough, but did not cause cell damage due to
Ca2+-excitotoxicity. Fractions to be tested were then co-incubated for
10min with a 45Ca2+ uptake solution, and the accumulation of the
radioactive tracer in the adhesive TRPV1-HaCaT cell line was de-
termined. For agonist activity tests, increasing concentrations of the
extracts were used instead of CAPS in the same assay. Pellitorin had no
eﬀect on the Ca2+ uptake of the non-transfected HaCaT cell line that
does not express a functional TRPV1 (data is not shown).
In contrast with expectations from previous studies, our extraction
procedure from T. daniellii fruits revealed potent antagonist activity.
The dose-response curves generated with the fraction Evo10 demon-
strated full antagonist eﬀect on the TRPV1 (Fig. 1B) with an eﬃcacy of
IC50= 215 µg/ml. CapZ, a bona ﬁde inhibitor of the TRPV1 compared
side-by-side in a 96 well plate assay (Fig. 1B), gave an IC50= 5.3 µg/ml
showing an only 40 times greater potency of inhibition than that of the
crude, but biologically active fraction Evo10.
A VLC procedure with the active fraction Evo10 resulted in the se-
paration of a set of apolar compounds. The fraction Evo10/1 preserved
the antagonist activity, the TRPV1-HaCaT cell-based bioassay resulting
in IC50= 57 µg/ml (Fig. 1C).
To attain complete homogeneity, fraction Evo10/1 was subjected to
OCC on the RP-18 stationary phase. This led to the separation of eight
fractions (Evo10/1A – Evo10/1H) of which Evo10/1B was the most
eﬀective as concerns CAPS-induced Ca2+ uptake (IC50= 32 µg/ml),
determined with the TRPV1-HaCaT cell line (Fig. 1D).
The ﬁnal step of Evo10/1B puriﬁcation by preparative TLC yielded a
pure compound. Structure analysis identiﬁed this TRPV1 inhibitor as
pellitorine (1). As a structural analogue of CAPS (2), it inhibited TRPV1
in a concentration-dependent manner with IC50= 154 µg/ml
(0.69 mM/l) (Fig. 2). The higher IC50 value of pellitorine compared that
of the Evo10/1B fraction might be caused by the potential loss of other
active components during the puriﬁcation procedure.
The extensive puriﬁcation procedures yielded fractions containing
other compounds that were puriﬁed either completely or nearly to
homogeneity; these were determined by 1H NMR spectrometry as: N-
isobutyl-4,5-epoxy-2E-decaenamide (3), one of the closest, though
surprisingly, completely inactive epoxy-derivatives of pellitorine; and
several coumarins such as 8-geranyloxypsoralen (5), 8-(7′,8′-epox-
ygeranyloxy)psoralen (7) and xanthotoxol (4), were also co-puriﬁed
(Fig. 4). None of these distant, xanthotoxol-derivatised homologues
were proved active in the functional TRPV1 bioassay. On the contrary,
a previous study investigated imperatorin, a furocoumarin that showed
weak agonist activity on TRPV1 (Chen et al., 2014).
Following in vitro tests, pellitorine was challenged in vivo tests of eye
wiping in response to pungent vanilloids. 3.75mM pellitorine applied
together with 100 µM CAPS signiﬁcantly (p=0016) decreased the
frequency of vanilloid-evoked defending movements (Fig. 3). The
number of eye wiping movements evoked by 100 µM CAPS, however,
did not change signiﬁcantly following either a 1 h or 15min pre-
treatment with 3.75mM or 4.5 mM pellitorine. Consequently, pelli-
torine inhibited the pain-evoked defensive movements of BALB/c mice
in response to pungent vanilloids.
To date, only TRPV1 agonists have been described from extracts of
Evodia species, compounds that are also known to induce the release of
inﬂammatory CGRP and substance P, both of them peptide agonists of
CGRP receptors and neurokinin receptors, respectively, and are in-
volved in the transmission of pain signals in second-order neurons of
the PNS (Kobayashi et al., 2001). However, in our research study the
cyclohexane-soluble phase was found to inhibit CAPS-induced Ca2+-
uptake in either HaCaT keratinocytes from human or NIH3T3 mouse
ﬁbroblasts (results not shown) expressing TRPV1 ectopically.
The “inﬂammatory soup” is rich in potent endogenous agonists of
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TRPV1, such as (but not conﬁned to) eicosanoids and prostaglandin
analogues. Anandamide, 15-(S)-hydroperoxyeicosatetraenoic acid (6),
5-, and 15-(S)-hydroxyeicosatetraenoic acids, leukotriene B(4), N-
oleoyldopamine, and N-oleoylethanolamine (8) are the best-known
endogenous algesics in inﬂammation (Chu et al., 2003; Olah et al.,
2001; Hwang et al., 2000). Similarly to skin-irritating phorbol esters,
certain polyunsaturated fatty acids (PUFAs), such as omega-3, have
been demonstrated to upregulate the TRPV1 via the protein kinase
mediated phosphorylation of Ser502 and Ser800 of TRPV1 (Matta et al.,
2007). Moreover, the activation of cyclooxygenase isozymes leads to
the generation of numbers of agonists showing structural similarity to
pellitorine.
Our study has provided the ﬁrst evidence that pellitorine, an ali-
phatic alkylamide analogue of CAPS, inhibits TRPV1. Evodia species are
recognised sources of bioactive substances, but previous studies in-
dicated only agonist activity on TRPV1 (Beak et al., 2004; Pearce et al.,
2004). 8-geranyloxypsoralen (5) and other coumarins, such as 8-(7′,8′-
epoxygeranyloxy)psoralen (7) and xanthotoxol (4) (Fig. 4), proved in-
active in our functional TRPV1 bioassay.
Conclusion
Pellitorine may also be considered as a structural homologue of
exovanilloids, however, it was found to be an antagonist rather than
agonist of TRPV1. Pellitorine, one of the natural substances of
Fig. 1. The eﬀect of fractions from Tetradium daniellii fruits on the TRPV1
A - Antagonist activity of the cyclohexane phase. Increasing concentrations of this fraction were added to TRPV1 expressing HaCaT cells in the presence of 2 µM CAPS-in 96 well plates for
10min with robotic liquid handling. Co-incubation of extracts reduced signiﬁcantly the vanilloid-induced 45Ca2+ uptake. The data are the means triplicate measurements with either
TRPV1-HaCaT or TRPV1-NIH3T3 permanent cell lines.
B - Antagonist activity of fraction Evo10. This fraction was added in increasing concentrations to TRPV1 expressing HaCaT cells in the presence of 2 µM CAPS-in 96 well plates for 10min
with robotic liquid handling. Co-incubation of extracts or CapZ reduced signiﬁcantly the vanilloid-induced 45Ca2+ uptake. The data are the means of triplicate measurements with either
TRPV1-HaCaT or TRPV1-NIH3T3 permanent cell lines.
C - Dose-dependent inhibition of the TRPV1 by VLC fractions Evo 10/1 – Evo 10/9. Evo10 was further separated into nine fractions (Evo 10/1 – Evo 10/9) diﬀering in composition by VLC
on silica gel with n-hexane – acetone mixtures of increasing polarity. The concentrated fractions were co-incubated with CAPS for 10min in the cell-based TRPV1 inhibition assay and
their IC50 values were determined. Fraction Evo 10/1 fully inhibited the activation of the TRPV1 with an IC50 of 57 µg/ml. The experiments were repeated in triplicate two additional
times with similar results.
D - Fractionation of VLC fraction Evo 10/1 by column chromatography was carried out on RP-18 silica gel with elution with MeOH/H2O mixtures. The eluted fractions were lyophilized
and then redissolved in EtOH and their activities were tested in CAPS-induced TRPV1-HaCaT cells. RP-CC fraction Evo10/1B inhibited the 45Ca2+-uptake. Each experiment was repeated
in triplicate at least two additional times with similar results.
Fig. 2. Proﬁling of inhibitory activity of pellitorine (1). The membrane transport of
45Ca2+ was characterized in the presence of progressively increasing concentrations of
pellitorine. Kinetics similar to that represented here was observed in two additional ex-
periments, carried out in duplicate samples.
Fig. 3. Eﬀects of pellitorine (1) on the pain sensation of BALB/c mice in eye wipe tests.
3.75 mM pellitorine applied together with 100 µM CAPS signiﬁcantly (p= 0.016, two-
tailed t-test) decreased the frequency of vanilloid-evoked defensive movements. The ex-
periment was performed 3 times, with similar results, group number≥ 7.
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Tetradium daniellii, and Piper longum l. (Liu et al., 2015), a new an-
tagonist of TRPV1 showed a completely diﬀerent chemical structure
than that of previously described potent antagonists of TRPV1. Co-
puriﬁed homologous compounds, that are either active or inactive on
TRPV1 Ca2+-channel activation, can serve as valuable lead structures
in medicinal chemistry in directing these pharmacophores to the ther-
apeutic target with improved speciﬁcity and eﬃcacy.
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